 Cellular senescence is a state of permanent cell growth arrest that occurs as a result of DNA damage and is characterized by resistance to apoptosis, acquisition of a pro-inflammatory phenotype, and accumulation of senescent cells in various tissues. This leads to a variety of age-related diseases and conditions, including chronic inflammation, metabolic dysregulation, stem cell dysfunction, and geriatric syndromes. Stenolytics, drugs that target senescent cells, have been developed to reduce senescent cell burden and alleviate multiple senescence-associated conditions. These drugs have shown promise in pre-clinical studies and are currently undergoing translation into clinical trials. This article was authored by James L. Kirkland and Tamaritconia.